|
Report No. : |
307933 |
|
Report Date : |
25.02.2015 |
IDENTIFICATION DETAILS
|
Name : |
GENEHARBOR (HONG KONG) BIOTECHNOLOGIES LTD. |
|
|
|
|
Registered Office : |
Unit 506-507, 5/F., Bio-Informatics Centre, 2 Science Park West
Avenue, Hong Kong Science Park, Shatin, New Territories |
|
|
|
|
Country : |
Hong Kong |
|
|
|
|
Date of Incorporation : |
01.06.2011 |
|
|
|
|
Com. Reg. No.: |
58453596 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Importer, Exporter and Manufacturer of All kinds of biochemical products |
|
|
|
|
No. of Employee : |
25 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Hong Kong |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
HONG KONG ECONOMIC OVERVIEW
Hong Kong has a free market economy, highly dependent on international trade and finance - the value of goods and services trade, including the sizable share of re-exports, is about four times GDP. Hong Kong has no tariffs on imported goods, and it levies excise duties on only four commodities, whether imported or produced locally: hard alcohol, tobacco, hydrocarbon oil, and methyl alcohol. There are no quotas or dumping laws. Hong Kong's open economy left it exposed to the global economic slowdown that began in 2008. Although increasing integration with China, through trade, tourism, and financial links, helped it to make an initial recovery more quickly than many observers anticipated, its continued reliance on foreign trade and investment leaves it vulnerable to renewed global financial market volatility or a slowdown in the global economy. The Hong Kong government is promoting the Special Administrative Region (SAR) as the site for Chinese renminbi (RMB) internationalization. Hong Kong residents are allowed to establish RMB-denominated savings accounts; RMB-denominated corporate and Chinese government bonds have been issued in Hong Kong; and RMB trade settlement is allowed. The territory far exceeded the RMB conversion quota set by Beijing for trade settlements in 2010 due to the growth of earnings from exports to the mainland. RMB deposits grew to roughly 12% of total system deposits in Hong Kong by the end of 2013. The government is pursuing efforts to introduce additional use of RMB in Hong Kong financial markets and is seeking to expand the RMB quota. The mainland has long been Hong Kong's largest trading partner, accounting for about half of Hong Kong's total trade by value. Hong Kong's natural resources are limited, and food and raw materials must be imported. As a result of China's easing of travel restrictions, the number of mainland tourists to the territory has surged from 4.5 million in 2001 to 34.9 million in 2012, outnumbering visitors from all other countries combined. Hong Kong has also established itself as the premier stock market for Chinese firms seeking to list abroad. In 2012 mainland Chinese companies constituted about 46.6% of the firms listed on the Hong Kong Stock Exchange and accounted for about 57.4% of the Exchange's market capitalization. During the past decade, as Hong Kong's manufacturing industry moved to the mainland, its service industry has grown rapidly. Credit expansion and tight housing supply conditions have caused Hong Kong property prices to rise rapidly; consumer prices increased by more than 4% in 2013. Lower and middle income segments of the population are increasingly unable to afford adequate housing. Hong Kong continues to link its currency closely to the US dollar, maintaining an arrangement established in 1983. In 2013, Hong Kong and China signed new agreements under the Closer Economic Partnership Agreement, adopted in 2003 to forge closer ties between Hong Kong and the mainland. The new measures, effective from January 2014, cover services and trade facilitation, and will improve access to the mainland's service sector for Hong Kong-based companies.
|
Source
: CIA |
GENEHARBOR (HONG
KONG) BIOTECHNOLOGIES LTD.
ADDRESS: Unit 506-507, 5/F.,
Bio-Informatics Centre, 2 Science Park West Avenue, Hong Kong Science Park,
Shatin, New Territories, Hong Kong.
PHONE: 852-2838
0306
FAX: 852-2834
4180
E-MAIL: info@geneharbor.com.hk
Managing Director: Mr. Wang Jun
Incorporated on: 1st June, 2011.
Organization: Private Limited Company.
Issued Share Capital: HK$1.00
Business Category: Importer,
Exporter and Manufacturer.
Employees: 25.
Main Dealing Banker: The
Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
Banking Relation: Satisfactory.
Registered Head
Office:-
Unit 506-507, 5/F., Bio-Informatics Centre, 2 Science Park West Avenue, Hong
Kong Science Park, Shatin, New Territories, Hong Kong.
Holding Company:-
GeneHarbor Holding Ltd., Bermuda.
Associated
Companies:-
Bioright Worldwide Co. Ltd., British Virgin Islands.
GeneHarbor (Hong Kong) Biotechnologies Ltd., British Virgin Islands.
GeneHarbor HK Ltd., Hong Kong.
GeneHarbor Investment Ltd., Hong Kong.
Jiangmen Biocarrier Technologies Ltd., China.
Jiangmen Biocatalyst Technologies Ltd., China.
Jiangmen Innocarrier Bio-Technologies Ltd., China.
58453596
1610458
Managing Director: Mr. Wang Jun
HK$1.00
(As per registry dated 01-06-2014)
|
Name |
|
No. of share |
|
GeneHarbor Holding Ltd. Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. |
|
1 = |
(As per registry dated 01-06-2014)
|
Name (Nationality) |
Address |
|
WANG Jun |
Flat C, 9/F., Block 10, Royal Ascot, Fotan, New Territories, Hong
Kong. |
(As per registry dated 01-06-2014)
|
Name |
Address |
|
Karenda NGAN |
Units 506-507, 5/F., Bio-Informatics Centre, 2 Science Park West
Avenue, HK Science Park, Shatin, New Territories, Hong Kong. |
The subject was incorporated on 1st June, 2011 as a private limited
liability company under the Hong Kong Companies Ordinance.
Apart from these, neither material change nor amendment has been ever
traced and noted.
Activities: Importer,
Exporter and Manufacturer.
Lines: All kinds of biochemical
products, etc.
Trade Mark: GeneHarbor.
Employees: 25.
Commodities Imported: China, other
Asian countries, etc.
Markets: Hong Kong,
China, other Asian countries, Europe, North America, etc.
Terms/Sales: As per contracted.
Terms/Buying: Various terms.
Issued Share Capital: HK$1.00
Profit or Loss: Made a small profit in 2014.
Condition: Keeping in a normal manner.
Facilities: Making rather active use of general banking facilities.
Payment: Met trade commitments as required.
Commercial Morality: Satisfactory.
Banker: The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
Standing: Normal.
GeneHarbor (Hong Kong) Biotechnologies Ltd. is a wholly-owned subsidiary
of GeneHarbor Holding Ltd. which is a Bermuda-registered company.
The only director of the subject Mr. Wang Jun is a China merchant. He is a Hong Kong ID Card holder and has got
the right to reside in Hong Kong permanently.
Currently he is residing in Hong Kong.
The subject acquired the business from GeneHarbor (Hong Kong)
Technologies Ltd. [GHHKTL] on 19th November, 2012.
GHHKTL was located at the same address.
The subject is a Hong Kong based biotech company which has been actively
engaged in the research, development, production, technology and marketing of
value-added biochemical. It is an
experienced manufacturer and exporter and is offering bio-tech products that
are formulated with the use of quality inputs and core methods. It offers range covers Dietary Supplements,
Dietary Fiber Supplements, GSH (L-Glutathione Reduced), SAG (S-Acetyl
Glutathione), NAD (Oxidized Coenzyme I), NADH (Nicotinamide Adenine Dinucleotide
Reduced), Protein A and Protein G, etc.
The subject produces economic, effective and environmentally friendly
solutions for various industries such as Pharmaceuticals, Dietary Supplement
and Cosmetics. Most of its products are
exported to the United States, India and China.
According to the subject, it has been one of the leading bio-tech
companies in the world.
The followings are the main products of the subject:-
The products are widely used in pharmaceuticals, functional foods,
dietary supplements, cosmetics, etc.
The subject’s products bear the trade mark GeneHarbor.
The trade mark GeneHarbor has registered with the Trade Marks
Registry, Intellectual Property Development, the Government of the Hong Kong
SAR. The filing date was 12th February,
2003 while the expiry date is 12th February, 2020. This trade mark is owned by Bioright
Worldwide Co. Ltd. which is a BVI-registered company. Bioright Worldwide is an associate of the
subject.
The subject has had the following China associates:-
All the China firms are engaged in the same lines of business as the
subject. The subject acquired the
above-mentioned companies in November 2012.
In March 2012, the subject’s associated company GeneHarbor Holdings Ltd.
wanted to dispose one of its companies to China HealthCare Holdings Ltd. which
was a Hong Kong listed company. However,
the acquisition and transference have been suspended.
Currently, the subject is looking for agents to distribute its products.
The history of the subject is just over three years and eight
months. On the whole, consider it good
for normal business engagements.
Brief personal profile of director:-
Dr. WANG Jun, Ph.D, CEO: Dr. Wang had been a professor at Biochemistry
Department, the Chinese University of Hong Kong for over 15 years. He has over 36 years of research experience
in China, the United States, Australia and Hong Kong. Dr. Wang held the first Industrial Research
Chair funded by Innovation and Technology Commission of Hong Kong
Government. He has acted as senior
advisors to several pharmaceutical companies.
Dr. Wang obtained his Ph.D in Molecular Biology from the University of
Wisconsin-Madison.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.27 |
|
|
1 |
Rs.96.21 |
|
Euro |
1 |
Rs.70.60 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.